AIM: £41.50 (-0.7) | Nasdaq: $26.97 (+0.22)
Search
EN
简
繁
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
CNBC Squawk Box
CEO Christian Hogg discusses savolitinib and fruquintinib progress
Watch Interview
FY2018 Results & Programs Update
Announcement and Presentation webcast
View Event Details
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Group
|
3 May 2019
Notice of Extraordinary General Meeting and Shareholders' Circular
Group
|
15 Apr 2019
Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
Innovation Platform
|
29 Mar 2019
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
Innovation Platform
|
28 Mar 2019
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting
Group
|
21 Mar 2019
2018 Annual Report and Notice of Annual General Meeting
Current Share Price
London AIM:HCM
£41.50
-0.7 | 23-May-2019 | 08:03 BST
Nasdaq:HCM
US$26.97
+0.22 | 22-May-2019 | 16:00 EST
Note: 1 Nasdaq share = ½ AIM share
Latest Presentations
8 May 2019
J.P. Morgan Global China Summit 2019
11 Mar 2019
2018 Full Year Results
4 Mar 2019
Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
7 Jan 2019
37th Annual J.P. Morgan Healthcare Conference
Latest Reports
Annual Report 2018 (with Form 20-F)
EN
Interim Report 2018
EN
Annual Report 2017 (with Form 20-F)
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison
HSBC
Panmure Gordon
Trinity Delta
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More